New ALS drugs should still use randomized, placebo-controlled trials to show efficacy, the US Food and Drug Administration says, but the agency clarified that it is not necessarily married to the traditional study design for the products.
In final guidance on development of drugs for amyotrophic lateral sclerosis (ALS), the agency included much more patient-focused language in describing study designs, likely in part to avoid recruitment...